Crescent Biopharma, Inc. Common Stock
Veridion Score
Composite trend over time
Why is CBIO moving today?
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CBIO.
CBIO insider activity
Crescent Biopharma, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CBIO.
CBIO contract awards, year to date.
Public federal awards linked to this ticker.
CBIO lobbying filings, year to date.
Registered lobbying filings matched to Crescent Biopharma, Inc. Common Stock.